Blood Reviews
Volume 23, Issue 3 , Pages 95-104 , May 2009

Ferritin for the clinician

References 

  1. Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol. 2007;69(69–85):69–85
  2. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986–1995
  3. Andrews NC. Understanding heme transport. N Engl J Med. 2005;353(23):2508–2509
  4. Anderson GJ, Frazer DM. Hepatic iron metabolism. Semin Liver Dis. 2005;25(4):420–432
  5. Heeney MM, Andrews NC. Iron homeostasis and inherited iron overload disorders: an overview. Hematol Oncol Clin North Am. 2004;18(6):1379–1403[ix]
  6. Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood. 2006;108(4):1388–1394
  7. Roy CN, Andrews NC. Anemia of inflammation: the hepcidin link. Curr Opin Hematol. 2005;12(2):107–111
  8. Taketani S. Acquisition, mobilization and utilization of cellular iron and heme: endless findings and growing evidence of tight regulation. Tohoku J Exp Med. 2005;205(4):297–318
  9. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99(10):3505–3516
  10. Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West J Med. 1986;145(5):657–663
  11. Hallberg L, Bengtsson C, Lapidus L, Lindstedt G, Lundberg PA, Hulten L. Screening for iron deficiency: an analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women. Br J Haematol. 1993;85(4):787–798
  12. Weiss G. Modification of iron regulation by the inflammatory response. Best Pract Res Clin Haematol. 2005;18(2):183–201
  13. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89(3):1052–1057
  14. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?. Clin J Am Soc Nephrol. 2006;1(Suppl. 1):S9–S18
  15. Coyne D. Iron indices: what do they really mean?. Kidney Int Suppl. 2006;(101):S4–S8
  16. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(Suppl. 1):S4–S8
  17. Guyatt GH, Oxman AD, Ali M, Willan A, McIlroy W, Patterson C. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med. 1992;7(2):145–153
  18. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221–230
  19. Bacon BR, Britton RS. Clinical penetrance of hereditary hemochromatosis. N Engl J Med. 2008;358(3):291–292
  20. Qaseem A, Aronson M, Fitterman N, Snow V, Weiss KB, Owens DK. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Annu Intern Med. 2005;143(7):517–521
  21. Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood. 2008;111(7):3373–3376
  22. Gordeuk V, Mukiibi J, Hasstedt SJ, et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med. 1992;326(2):95–100
  23. Gordeuk VR, Caleffi A, Corradini E, et al. Iron overload in Africans and African–Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis. 2003;31(3):299–304
  24. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol. 2007;138(4):407–421
  25. Barton JC. Optimal management strategies for chronic iron overload. Drugs. 2007;67(5):685–700
  26. Porter JB. Monitoring and treatment of iron overload: state of the art and new approaches. Semin Hematol. 2005;42(2 Suppl. 1):S14–S18
  27. Magri D, Sciomer S, Fedele F, et al. Early impairment of myocardial function in young patients with beta-thalassemia major. Eur J Haematol. 2008;80(6):515–522
  28. Stumpf JL. Deferasirox. Am J Health Syst Pharm. 2007;64(6):606–616
  29. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood. 2003;101(9):3359–3364
  30. Sheth S, Tang H, Jensen JH, et al. Methods for noninvasive measurement of tissue iron in Cooley’s anemia. Ann N Y Acad Sci. 2005;1054:358–372
  31. Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007;14(3):183–190
  32. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2∗ mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460–1465
  33. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2∗) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–2179
  34. St Pierre TG, Clark PR, Chua-Anusorn W. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. Ann N Y Acad Sci. 2005;1054:379–385
  35. St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855–861
  36. Carneiro AA, Fernandes JP, de Araujo DB, et al. Liver iron concentration evaluated by two magnetic methods: magnetic resonance imaging and magnetic susceptometry. Magn Reson Med. 2005;54(1):122–128
  37. Zandman-Goddard G, Shoenfeld Y. Ferritin in autoimmune diseases. Autoimmun Rev. 2007;6(7):457–463
  38. Uppal SS, Al-Mutairi M, Hayat S, Abraham M, Malaviya A. Ten years of clinical experience with adult onset Still’s disease: is the outcome improving?. Clin Rheumatol. 2007;26(7):1055–1060
  39. Evensen KJ, Swaak TJ, Nossent JC. Increased ferritin response in adult Still’s disease: specificity and relationship to outcome. Scand J Rheumatol. 2007;36(2):107–110
  40. Sekigawa I, Suzuki J, Nawata M, et al. Hemophagocytosis in autoimmune disease. Clin Exp Rheumatol. 2001;19(3):333–338
  41. Emmenegger U, Schaer DJ, Larroche C, Neftel KA. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly. 2005;135(21–22):299–314
  42. Emmenegger U, Frey U, Reimers A, et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol. 2001;68(1):4–10
  43. Cazzola M, Invernizzi R, Bergamaschi G, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood. 2003;101(5):1996–2000
  44. la Porta MG, Malcovati L, Invernizzi R, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia. 2006;20(4):549–555
  45. Jaffe ES, 1943-World Health Organization. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; Oxford: Oxford University Press (Distributor); 2001.
  46. Haddad AS, Subbiah V, Lichtin AE, Theil KS, Maciejewski JP. Hypocupremia and bone marrow failure. Haematologica. 2008;93(1):e1–e5
  47. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci. 2007;30:317–337
  48. Thomas M, Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol. 2004;17(4):437–442
  49. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci. 2007;30:317–337
  50. Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson’s disease. Ann N Y Acad Sci. 2004;1012:193–208
  51. Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord. 2005;20(10):1278–1285
  52. Hirsch EC. Biochemistry of Parkinson’s disease with special reference to the dopaminergic systems. Mol Neurobiol. 1994;9(1–3):135–142
  53. Waldvogel D, van GP, Hallett M. Increased iron in the dentate nucleus of patients with Friedreich’s ataxia. Ann Neurol. 1999;46(1):123–125
  54. Boddaert N, Le Quan Sang KH, Rotig A, et al. Selective iron chelation in Friedreich Ataxia: biologic and clinical implications. Blood. 2007;110(1):401–408
  55. Levi S, Cozzi A, Arosio P. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract Res Clin Haematol. 2005;18(2):265–276
  56. Kotagal S, Silber MH. Childhood-onset restless legs syndrome. Ann Neurol. 2004;56(6):803–807
  57. Hogl B, Kiechl S, Willeit J, et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology. 2005;64(11):1920–1924
  58. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54(8):1698–1700
  59. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61(3):304–309
  60. Bonneau D, Winter-Fuseau I, Loiseau MN, et al. Bilateral cataract and high serum ferritin: a new dominant genetic disorder?. J Med Genet. 1995;32(10):778–779
  61. Girelli D, Corrocher R, Bisceglia L, et al. Molecular basis for the recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the “Verona mutation”). Blood. 1995;86(11):4050–4053
  62. Bonneau D, Winter-Fuseau I, Loiseau MN, et al. Bilateral cataract and high serum ferritin: a new dominant genetic disorder?. J Med Genet. 1995;32(10):778–779
  63. You SA, Wang Q. Ferritin in atherosclerosis. Clin Chim Acta. 2005;357(1):1–16
  64. de Godoy MF, Takakura IT, Machado RD, Grassi LV, Nogueira PR. Serum ferritin and obstructive coronary artery disease: angiographic correlation. Arq Bras Cardiol. 2007;88(4):430–433
  65. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803–811
  66. Klipstein-Grobusch K, Koster JF, Grobbee DE, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999;69(6):1231–1236
  67. Tuomainen TP, Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ. 1997;314(7083):793–794
  68. Liu X, Theil EC. Ferritin as an iron concentrator and chelator target. Ann N Y Acad Sci. 2005;1054:136–140
  69. Kabat GC, Rohan TE. Does excess iron play a role in breast carcinogenesis? an unresolved hypothesis. Cancer Causes Control. 2007;18(10):1047–1053
  70. Elliott RL, Elliott MC, Wang F, Head JF. Breast carcinoma and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study. Ann N Y Acad Sci. 1993;698:159–166
  71. Weinstein RE, Bond BH, Silberberg BK. Tissue ferritin concentration in carcinoma of the breast. Cancer. 1982;50(11):2406–2409
  72. Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet. 1980;2(8191):390–392
  73. Marcus DM, Zinberg N. Measurement of serum ferritin by radioimmunoassay: results in normal individuals and patients with breast cancer. J Nat Cancer Inst. 1975;55(4):791–795
  74. Rossiello R, Carriero MV, Giordano GG. Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J Clin Pathol. 1984;37(1):51–55
  75. Ionescu JG, Novotny J, Stejskal V, Latsch A, Blaurock-Busch E, Eisenmann-Klein M. Increased levels of transition metals in breast cancer tissue. Neuro Endocrinol Lett. 2006;27 Suppl. 1:36–39
  76. Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Curr Med Chem. 2003;10(12):1021–1034
  77. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586–4588
  78. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417–421
  79. Storey JA, Connor R, Lewis ZT, et al. The transfusion iron overload score is a potential predictor of survival in stem cell transplant patients. Blood. 2007;110(11):336A
  80. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586–4588
  81. Altes A, Remacha AF, Sureda A, et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(12):987–989
  82. Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Natural resistance, iron and infection: a challenge for clinical medicine. J Med Microbiol. 2006;55(Pt 3):251–258
  83. Altes A, Remacha AF, Sarda P, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant. 2004;34(6):505–509
  84. Altes A, Remacha AF, Sarda P, et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol. 2007;86(6):443–447
  85. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 1993;329(12):840–844
  86. Massover WH. Alpha 2-macroglobulin: a ferritin-binding protein. Ann N Y Acad Sci. 1994;737:468–471
  87. Seki T, Kunichika T, Watanabe K, Orino K. Apolipoprotein B binds ferritin by hemin-mediated binding: evidence of direct binding of apolipoprotein B and ferritin to hemin. Biometals. 2008;21(1):61–69
  88. Torti SV, Torti FM. Human H-kininogen is a ferritin-binding protein. J Biol Chem. 1998;273(22):13630–13635
  89. Schmaier AH, McCrae KR. The plasma kallikrein-kinin system: its evolution from contact activation. J Thromb Haemost. 2007;5(12):2323–2329
  90. Barnes PJ. Effect of bradykinin on airway function. Agents Actions Suppl. 1992;38(Pt 3):432–438
  91. Sainz IM, Pixley RA, Colman RW. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost. 2007;98(1):77–83
  92. Stewart JM, Gera L, Chan DC, et al. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides. 2005;26(8):1288–1291
  93. Parthasarathy N, Torti SV, Torti FM. Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release. Biochem J. 2002;365(Pt 1):279–286
  94. Coffman LG, Brown JC, Johnson DA, et al. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol. 2008;294(3):L505–L515

PII: S0268-960X(08)00066-0

doi: 10.1016/j.blre.2008.08.001

Blood Reviews
Volume 23, Issue 3 , Pages 95-104 , May 2009

Article Tools

* Image Usage & Resolution